Consensus $77.1M. Sees FY24 gross margin 72%-74%. The company said, “NeuroPace (NPCE) continues to expect revenue growth to be primarily driven by increasing sales of its RNS System, supported by higher sales of DIXI Medical stereo EEG products.”
Consensus $77.1M. Sees FY24 gross margin 72%-74%. The company said, “NeuroPace (NPCE) continues to expect revenue growth to be primarily driven by increasing sales of its RNS System, supported by higher sales of DIXI Medical stereo EEG products.”